Calliditas Therapeutics AB (CALT)

The total asset value of Calliditas Therapeutics AB (CALT) stood at $ 1,953 Mln as on 31-Dec-22

The share price of Calliditas Therapeutics AB (CALT) is $18.78 (NASDAQ) as of 28-Nov-2023 14:31 EST. Calliditas Therapeutics AB (CALT) has given a return of -17.27% in the last 3 years.

Calliditas Therapeutics AB (CALT) has a market capitalisation of $ 470 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Calliditas Therapeutics AB (CALT) is 7.39 times as on 02-Jun-2023, a 1.91% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Calliditas Therapeutics AB (CALT) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Calliditas Therapeutics AB (CALT) and enter the required number of quantities and click on buy to purchase the shares of Calliditas Therapeutics AB (CALT).

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

The CEO & director of Ms. Renee Aguiar-Lucander. is Calliditas Therapeutics AB (CALT), and CFO & Sr. VP is Mr. Fredrik Johansson.

The promoters of Calliditas Therapeutics AB (CALT) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Calliditas Therapeutics AB (CALT) was $-409 Mln.